Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 229Leukemia, Lymphocytic, Chronic, B-Cell 213Leukemia 203Myelodysplastic Syndromes 185Precursor Cell Lymphoblastic Leukemia-Lymphoma 174Lymphoma 148Lymphoma, Non-Hodgkin 142Multiple Myeloma 131Hodgkin Disease 123Lymphoma, Follicular 111Lymphoma, Mantle-Cell 108Lymphoma, Large B-Cell, Diffuse 96Lymphoma, B-Cell, Marginal Zone 89Myeloproliferative Disorders 86Congenital Abnormalities 85Burkitt Lymphoma 85Leukemia, Myelomonocytic, Chronic 77Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myeloid, Accelerated Phase 73Recurrence 63Melanoma 62Lymphoma, Large-Cell, Immunoblastic 61Anemia, Refractory, with Excess of Blasts 60Neoplasms, Plasma Cell 56Waldenstrom Macroglobulinemia 55Primary Myelofibrosis 55Blast Crisis 55Hematologic Neoplasms 45Lymphoma, T-Cell, Cutaneous 42

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × fludarabine phosphate × Clear all
NCT05767359 2026-03-12

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
20 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡